Barclays PLC Has $325,000 Stock Position in MacroGenics, Inc. (NASDAQ:MGNX)

Barclays PLC increased its stake in shares of MacroGenics, Inc. (NASDAQ:MGNX) by 97.1% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 98,753 shares of the biopharmaceutical company’s stock after purchasing an additional 48,639 shares during the period. Barclays PLC’s holdings in MacroGenics were worth $325,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. XTX Topco Ltd bought a new position in MacroGenics during the third quarter worth about $37,000. China Universal Asset Management Co. Ltd. raised its position in shares of MacroGenics by 64.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,064 shares of the biopharmaceutical company’s stock valued at $40,000 after acquiring an additional 4,707 shares during the period. SG Americas Securities LLC bought a new position in MacroGenics during the 3rd quarter worth approximately $55,000. DRW Securities LLC acquired a new position in MacroGenics during the second quarter valued at approximately $56,000. Finally, XML Financial LLC raised its holdings in MacroGenics by 66.0% in the third quarter. XML Financial LLC now owns 17,600 shares of the biopharmaceutical company’s stock worth $58,000 after purchasing an additional 7,000 shares during the period. Institutional investors own 96.89% of the company’s stock.

MacroGenics Trading Up 4.8 %

Shares of MGNX opened at $3.46 on Friday. MacroGenics, Inc. has a 12 month low of $2.95 and a 12 month high of $21.88. The firm has a fifty day simple moving average of $3.51 and a 200 day simple moving average of $3.76. The stock has a market capitalization of $217.16 million, a price-to-earnings ratio of -2.19 and a beta of 2.04.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on MGNX. Evercore ISI upgraded shares of MacroGenics to a “strong-buy” rating in a research report on Monday, September 16th. StockNews.com upgraded MacroGenics from a “sell” rating to a “buy” rating in a report on Sunday, November 10th. HC Wainwright reaffirmed a “neutral” rating and set a $4.00 price target on shares of MacroGenics in a research report on Wednesday, November 6th. Finally, JMP Securities cut MacroGenics from an “outperform” rating to a “market perform” rating in a research note on Thursday, November 7th. Eight analysts have rated the stock with a hold rating, three have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat.com, MacroGenics has a consensus rating of “Hold” and a consensus price target of $7.63.

MacroGenics Profile

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.